HIV/AIDS INFORMATION CENTER

News

Glecaprevir/Pibrentasvir Is Safe, Efficacious for HCV/HIV-1 Coinfection

Glecaprevir/Pibrentasvir Is Safe, Efficacious for HCV/HIV-1 Coinfection

Analysis of 2 phase 3 clinical trials evaluating the safety/efficacy of glecaprevir/pibrentasvir in people with HCV coinfected with HIV-1 found an overall sustained virologic response of 98% at week 12 of treatment in those with or without cirrhosis.

A Single Combination Tablet Suppresses HIV Load Through 48 Weeks

A combination single tablet once-a-day regimen of doravirine/lamivudine/tenofovir disoproxil fumarate demonstrated non-inferiority and no significant adverse events when compared with continuation of established antiretroviral therapy in adults infected with HIV-1.

HIV Infection Diagnoses on the Rise in Young Homosexual Men

Number of HIV diagnoses in those aged 13 to 29 4x higher than those aged 50 years.

Opinion

The origin of AIDS and debating the Patient Zero theory

There is evidence that HIV might have spread from its origins in the US to the rest of the world.

HIV complacency can be deadly

It's been 32 years since the CDC published the first HIV case report, and too many Americans no longer view the disease as a serious illness.

Features

Healthcare issues of the LGBT community: What the primary care clinician should know

Healthcare issues of the LGBT community: What the primary care clinician should know

A greater understanding of the healthcare issues specific to the lesbian, gay, bisexual, and transgender community may improve the quality of care.

Initiating antiretroviral therapy in HIV patients with CD4 T-cell counts >500 cells/mcL

Initiating antiretroviral therapy in HIV patients with CD4 T-cell counts >500 cells/mcL

Recommendations for initiation of antiretroviral therapy (ART) in asymptomatic adults with HIV are generally based on CD4 T-cell counts.

Sign Up for Free e-newsletters